Skip to main content

Treatment Clinical Trials for Prostate Cancer

Review the prostate cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 201-225 of 302

An Investigational Scan (HP 13C MRI) for Assessing Response to Treatment with Abiraterone Acetate and Prednisone prior to Surgery in Patients with High-Risk Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
Ivonescimab for the Treatment of Patients with Locally Advanced, Unresectable and/or Metastatic Cutaneous Squamous Cell Cancer and Metastatic Castration-resistant Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
High Dose Rate Brachytherapy in Treating Patients with Prostate Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Status: Active
Location: 2 locations
Cell Therapy (STEAP1 CART) with Enzalutamide for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
Evaluation of 177Lu rhPSMA-10.1 and Degarelix before Radical Prostatectomy in Patients with High-Risk Localized Prostate Cancer, Nautilus Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Abemaciclib before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 2 locations
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
High-Dose Rate Brachytherapy Boost with Stereotactic Radiation Body Therapy to the Prostate and Pelvic Lymph Nodes for the Treatment of Unfavorable Intermediate or Higher Risk Prostate Cancer
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Stereotactic Body Radiation Therapy and 177Lu-PSMA-617 for the Treatment of Locally Advanced Prostate Cancer, STARLiT Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Status: Active
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
REGN5678 before Surgery for Treating Patients with High-Risk Localized Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Status: Active
Location: University of California San Francisco, San Francisco, California
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida